 | ||||||
| Ebola | ||||||
| NEWS | ||||||
| Institutional Investor's Pro-Novavax Inc (NASDAQ:NVAX) Sentiment In 2017 Q3 It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. The stock decreased 4.62% or $0.06 during the last trading session, reaching ...
| ||||||
| See more results | Edit this alert | ||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
Tidak ada komentar:
Posting Komentar